

SUPPLEMENTARY DATA

Table 1 of the supplementary data

Procedural and postprocedural data.

	Total cohort (n = 184)	I (n = 115)	IIa (n = 46)	IIb (n = 23)	P
<i>Balloon expandable prosthesis</i>	105 (57.1%)	70 (60.9%)	23 (50%)	12 (52.2%)	.60
<i>Percutaneous femoral access</i>	170 (92.4%)	106 (92%)	42 (91.3%)	22 (95.7%)	.89
Post-TAVI aortic regurgitation					.57
- 0	95 (51.6%)	58 (50.4%)	28 (60.9%)	9 (39.1%)	
- 1	68 (37%)	45 (39.1%)	13 (28.3%)	10 (43.5%)	
- 2	17 (9.2%)	10 (8.7%)	4 (8.7%)	3 (13.0%)	
- 3	1 (0.5%)	1 (0.9%)	1 (2.2%)	0	
<i>Post-TAVI mean aortic gradient (mmHg)</i>	11.5 (± 5)	11.6 (± 5)	11.8 (± 5)	10.0 (± 4)	.33
Periprocedural complications					
- Major bleeding	7 (3.8%)	4 (3.5%)	0	3 (13%)	.06
- Cardiogenic shock	2 (1.1%)	0	1 (2.2%)	1 (4.3%)	.77
- Pacemaker (n = 173)	12 (6.9%)	6 (5.5%)	5 (11.6%)	1 (4.8%)	.22
- In-hospital death	2 (1.1%)	0	0	2 (8.7%)	.008
<i>Length of stay (median)</i>	4 (3)	4 (3)	5 (3)	7 (11)	.23

TAVI, transcatheter aortic valve implantation.

Qualitative variables are expressed as total number (percentage), mean aortic gradient is expressed as mean mmHg \pm standard deviation, length of stay as median days [interquartile range].

Table 2 of the supplementary data

Changes in NT-proBNP levels (pg/mL).

Group	Baseline NT-proBNP	Preprocedural NT-proBNP	Absolute change	% Change	<i>P</i>
Group I	901 (1051)	872 (1142)	-49 (342)	-6,8% (46)	.06
Group IIa	3052 (4782)	2960 (3862)	-295 (2118)	-18,6% (47)	< .001
Group IIb	5571 (8385)	4664 (8635)	0 (1823)	0 (51)	.82

Values expressed as median [interquartile range].

Table 3 of the supplementary data

Univariate analysis of death and heart failure admission at follow-up.

	HR	95%CI	<i>P</i>
Age	1.06	1.01-1.12	.04
Sex	1.40	0.85-2.30	.18
Body mass index	1.03	0.96-1.10	.40
Hypertension	2.15	0.67-6.87	.29
Type 2 diabetes mellitus	1.34	0.82-2.21	.25
Dyslipidemia	0.66	0.40-1.09	.11
Smoking	1.46	0.80-2.64	.21
Previous myocardial infarction	1.64	0.87-3.08	.12
Previous coronary revascularization	1.94	1.13-3.32	.02
Previous valvular surgery	1.27	0.18-9.23	.81
Peripheral artery disease	0.48	0.12-1.95	.30
Cerebrovascular disease	1.22	0.49-3.04	.67
Atrial fibrillation	3.21	1.92-5.38	< .001
Previous pacemaker	2.15	0.92-5.02	.08
Right Bundle Branch Block	2.32	1.28-4.20	.006
Left Bundle Branch Block	0.83	0.36-1.93	.66
Glomerular filtration rate — mL/min	0.98	0.97-0.99	< .001
Hemoglobin	0.81	0.69-0.93	.004
New York Heart Association	2.09	1.47-2.96	< .001
Frailty (Fried \geq 3)	0.34	0.69-2.87	.34
STS score	1.01	0.94-1.10	.73

LVEF	0,98	0.96-1.01	.10
LVEF ≥ 50%	0.81	0.42-1.55	.53
Mean aortic gradient — mmHg	0.98	0.95-1.01	.16
Moderate or severe mitral regurgitation	1.09	0.62-1.90	.76
sPAP — mmHg	1.01	0.99-1.2	.57
Coronary stenosis	1.34	0.80-2.24	.26
Treatment			
MRA	3.07	1.66-5.67	< .001
ACEI	0.76	0.45-1.28	.30
Betablocker	0.92	0.55-1.52	.74

95%CI, 95% confidence interval; ACEI, angiotensin-converting enzyme inhibitors; HR, hazard ratio; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; sPAP, systolic pulmonary artery pressure; STS, Society of Thoracic Surgeons.